"We are delighted in the continuing progress we are making in cash flow and EBITDA," Garrett added. "For the first nine months of 2007, free cash flow improved by $55.6 million to $61.3 million. On an adjusted basis trailing-twelve months EBITDA increased by $61 million compared to EBITDA for the full year 2006. We expect these positive trends to continue."
Full Year Outlook
Garrett concluded, "Our clinical diagnostics business is strong, up 9.8% in constant currency through the first nine months. This gives us confidence that we should achieve our full year outlook for total company revenue growth of 7% to 9% enabling us to fund a higher level of investment in important growth areas like molecular diagnostics. We expect 2007 operating income margin to be around 12% on a comparable basis. Adjusted non-operating expense is expected to be flat with prior year. Pretax profit growth should be 10% to 15% over 2006 on a comparable basis. Our estimate for the full year tax rate has changed to between 28% and 29%. With the first nine months completed, we are now able to narrow the range for earnings per share to $3.15 to $3.22. Full year capital expenditures are expected to be $325 to $350 million and depreciation and amortization should be between $210 and $230 million."
"We're pleased with the advances our company is making in 2007. Clearly, we are making the improvements and creating the capabilities necessary for achieving our goal of sustainable growth well above historical rates," he said.
Investor Conference Call
As previously announced, there will be a conference call today,
Tuesday, October 30, 2007 at 8:30 am ET to discuss the third quarter ended
September 30, 2007 results. The call will also be webcast live. The call is
accessible to all investors through Beckman Coulter's website at
|SOURCE Beckman Coulter, Inc.|
Copyright©2007 PR Newswire.
All rights reserved